Sign in to view content

Efficacy and Durability of Brolucizumab in Patients Being Transitioned From Prior Anti-VEGF Therapy

Scott D Walter, MD, MSc, FASRS

Video
Published 2021

Related

Ladder Phase 2 Trial of the Port Delivery System With Ranibizumab (PDS) End of Study Results
David A. Eichenbaum, MD, FASRS
Annual Meeting Talks
2020
Economic Benefit of Higher Durability Anti-VEGF Agents in the Treatment of Neovascular Macular Degeneration
Sabin Dang, MD
Annual Meeting Talks
2023
Office Based Flicker ERG for Monitoring the Course of CRVO and HRVO Treated With Intravitreal Anti-VEGF and Suprachoroidal Triamcinolone Therapy
John J. Wroblewski, MD
Annual Meeting Talks
2021

Category: AMD-Neovascular

See more